ACAAI: Gene-Editing Therapy Reduces Angioedema Attacks in Hereditary Angioedema
By Elana Gotkine HealthDay Reporter
THURSDAY, Oct. 24, 2024 -- For adults with hereditary angioedema, the in vivo gene-editing therapy NTLA-2002, which is based on clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9, administered as a single dose reduces angioedema attacks, according to a study published online Oct. 24 in the New England Journal of Medicine to coincide with the annual meeting of the American College of Allergy, Asthma & Immunology, held from Oct. 24 to 28 in Boston.
Danny M. Cohn, M.D., Ph.D., from the Amsterdam University Medical Center, and colleagues randomly assigned adults with hereditary angioedema to receive NTLA-2002 in a single dose of 25 mg or 50 mg or placebo in a 2:2:1 ratio (10, 11, and six patients, respectively). The number of angioedema attacks per month from week 1 to 16 was the primary end point.
The researchers found that the estimated mean monthly attack rate was 0.70, 0.65, and 2.82 with 25-mg NTLA-2002, 50-mg NTLA-2002, and placebo, respectively (differences, −75 and −77 percent, respectively, compared with placebo). Overall, 40 and 73 percent of the patients who received 25-mg and 50-mg NTLA-2002, respectively, were attack-free with no additional treatment during the period from weeks 1 to 16. Headache, fatigue, and nasopharyngitis were the most common adverse events among patients receiving NTLA-2002.
"These results show the potential of a single dose of the new CRISPR-Cas9-based in vivo gene editing therapy NTLA-2002 to be a functional cure for patients with hereditary angioedema and support continued investigation in a larger phase 3 trial," the authors write.
The study was funded by Intellia Therapeutics, which is developing NTLA-2002.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Random Forest AI Model Superior for Inpatient Mortality Prognostication in Cirrhosis
THURSDAY, July 24, 2025 -- For inpatients with cirrhosis, a machine learning (ML) model using random forest (RF) analysis is superior for prediction of inpatient mortality...
Inflammation and Nutrition-Based Scores Tied to Prognosis of Low-Risk Myelodysplastic Syndrome
THURSDAY, July 24, 2025 -- The Prognostic Nutritional Index (PNI) and systemic oxidative stress (SOS) score are independently associated with poorer prognosis of low-risk...
Few School Principals Report District-Mandated Mental Health Screening
THURSDAY, July 24, 2025 -- Few school principals report district-mandated mental health screening in schools, according to a study published online July 18 in JAMA Network...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.